Vanguard Group Inc. Grows Position in SiBone $SIBN

Key Points

• Vanguard Group Inc. increased its holdings in SiBone (SIBN) by 1.5%, now owning 5.75% of the company's shares worth approximately $34.3 million.
• In its latest quarterly earnings report, SiBone reported a revenue of $48.63 million, exceeding analyst expectations, and a loss of ($0.14) EPS, better than the projected loss of ($0.19).
• Multiple institutional investors have adjusted their stakes in SiBone, with hedge funds owning an impressive 98.11% of the company's stock.

Vanguard Group Inc. raised its stake in shares of SiBone (NASDAQ:SIBN - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,444,159 shares of the company's stock after acquiring an additional 35,349 shares during the period. Vanguard Group Inc. owned about 5.75% of SiBone worth $34,292,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in SiBone by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after acquiring an additional 988 shares in the last quarter. Invesco Ltd. lifted its stake in SiBone by 8.9% during the 4th quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after acquiring an additional 1,413 shares in the last quarter. Rhumbline Advisers lifted its stake in SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after acquiring an additional 2,100 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new position in SiBone during the 1st quarter valued at $34,000. Finally, Barclays PLC lifted its stake in SiBone by 2.7% during the 4th quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after acquiring an additional 2,589 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

SiBone Stock Performance

SiBone stock traded up $0.05 during midday trading on Friday, reaching $16.67. The stock had a trading volume of 197,393 shares, compared to its average volume of 504,886. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The firm's 50-day moving average price is $17.01 and its 200 day moving average price is $16.51. The firm has a market capitalization of $719.14 million, a PE ratio of -29.77 and a beta of 0.91. The company has a quick ratio of 7.00, a current ratio of 8.38 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%.The business had revenue of $48.63 million for the quarter, compared to analysts' expectations of $48.12 million. SiBone has set its FY 2025 guidance at EPS. As a group, research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SIBN. Truist Financial raised their price objective on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Wall Street Zen cut SiBone from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald set a $25.00 target price on SiBone and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $23.67.

Insiders Place Their Bets

In other SiBone news, CEO Laura Francis sold 11,343 shares of SiBone stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.60, for a total transaction of $176,950.80. Following the completion of the transaction, the chief executive officer owned 419,704 shares of the company's stock, valued at $6,547,382.40. The trade was a 2.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Gordon Freund sold 12,132 shares of SiBone stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $15.99, for a total value of $193,990.68. Following the transaction, the director directly owned 91,767 shares of the company's stock, valued at $1,467,354.33. The trade was a 11.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 49,967 shares of company stock worth $829,469 in the last ninety days. 4.00% of the stock is owned by corporate insiders.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.